FXYD5

Across TCGA pan-cancer cohorts, FXYD5 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of FXYD5’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where FXYD5 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types FXYD5 is over-expressed in tumor, although a few such as LSCC and HNSC show the opposite, repressed pattern.

LSCC, CCRCC, and HNSC are the cancer types where FXYD5 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FXYD5 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Male	III,IV	−0.393	<.001	9	view →
CCRCC	Male	III,IV	+0.320	<.001	9	view →
HNSC	Male	IV	−0.391	<.001	8	view →
COAD	All	All	−0.279	.014	4	view →
PDAC	All	All	−0.284	.005	3	view →
OV	All	All	−0.656	.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

FXYD5–LSCC

Open the LSCC breakdown →